Mereo BioPharma Group plc

Share Issue/Capital Change • Nov 27, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8999U

Mereo BioPharma Group plc

27 November 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director Dealing

London, November 27, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on November 26, 2019, Richard Jones, Chief Financial Officer of Mereo, purchased 26,100 Ordinary Shares at a price of GBP0.38 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

Price(s)	Volume(s)
GBP0.38	26,100

d)

Aggregated information: volume, Price

Aggregated volume: 26,100

Aggregated price: GBP0.379

e)

Date of the transaction

2019-11-26

f)

Place of the transaction

AIMX

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBRBFTMBMTBPL